IN2014DN07132A - - Google Patents

Info

Publication number: IN2014DN07132A
Authority: IN; India
Prior art keywords: patients; treatment; methods; invention relate; including light
Prior art date: 2012-01-26

Application number

Other languages

English (en)

Inventor

Marlene Michelle Dressman

Louis William Licamele

Mihael H Polymeropoulos

Original Assignee

Vanda Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-26

Filing date

2013-01-25

Publication date

2015-04-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47679075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-01-25 Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc

2015-04-24 Publication of IN2014DN07132A publication Critical patent/IN2014DN07132A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2864—Sleep disorders
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Medical Informatics (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Data Mining & Analysis (AREA)
Databases & Information Systems (AREA)

IN7132DEN2014 2012-01-26 2013-01-25 IN2014DN07132A (es)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201261590974P	2012-01-26	2012-01-26
US201261640067P	2012-04-30	2012-04-30
US201261650455P	2012-05-22	2012-05-22
US201261650458P	2012-05-22	2012-05-22
US201261714149P	2012-10-15	2012-10-15
US201261738987P	2012-12-18	2012-12-18
US201261738985P	2012-12-18	2012-12-18
US201361755896P	2013-01-23	2013-01-23
PCT/US2013/023315 WO2013112951A2 (en)	2012-01-26	2013-01-25	Treatment of circadian rhythm disorders

Publications (1)

Publication Number	Publication Date
IN2014DN07132A true IN2014DN07132A (es)	2015-04-24

Family

ID=47679075

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IN7050DEN2014 IN2014DN07050A (es)	2012-01-26	2013-01-25
IN7132DEN2014 IN2014DN07132A (es)	2012-01-26	2013-01-25

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IN7050DEN2014 IN2014DN07050A (es)	2012-01-26	2013-01-25

Country Status (21)

Country	Link
US (22)	US8785492B2 (es)
EP (5)	EP2806864B1 (es)
JP (10)	JP2015508157A (es)
KR (10)	KR102171965B1 (es)
CN (4)	CN104519877A (es)
AU (9)	AU2013211878A1 (es)
BR (2)	BR112014018429A8 (es)
CA (4)	CA3085116C (es)
CL (2)	CL2014001993A1 (es)
CO (2)	CO7131353A2 (es)
DK (1)	DK2806863T3 (es)
ES (2)	ES2897671T3 (es)
HR (1)	HRP20171600T1 (es)
HU (1)	HUE034876T2 (es)
IL (4)	IL233714A0 (es)
IN (2)	IN2014DN07050A (es)
MX (4)	MX374068B (es)
PT (1)	PT2806863T (es)
RU (2)	RU2631602C2 (es)
SI (1)	SI2806863T1 (es)
WO (2)	WO2013112951A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2028937E (pt) *	2006-05-22	2015-04-09	Vanda Pharmaceuticals Inc	Tratamento por agonista de melatonina
US9532952B2 (en)	2011-01-28	2017-01-03	Physician's Seal, LLC	Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en)	2011-01-28	2012-08-02	Zx Pharma, Llc	Controlled-release melatonin composition and related methods
US11918557B2 (en)	2012-01-26	2024-03-05	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
CA3085116C (en)	2012-01-26	2022-07-19	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
JP5959083B2 (ja)	2012-05-18	2016-08-02	ヴァンダファーマシューティカルズインコーポレイテッド	（１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物
KR102148990B1 (ko) *	2012-12-18	2020-08-27	반다 파마슈티칼즈, 인코퍼레이티드.	일주기 리듬 장애의 치료
US11090285B2 (en)	2013-11-12	2021-08-17	Vanda Pharmaceuticals Inc	Treatment of circadian rhythm disorders
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
WO2015117048A1 (en) *	2014-01-31	2015-08-06	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
AU2015312252B2 (en)	2014-09-02	2020-07-02	Vanda Pharmaceuticals Inc.	Tasimelteon for treating Smith-Magenis Syndrome
US10076286B1 (en)	2014-10-21	2018-09-18	Verily Life Sciences Llc	Methods and devices for circadian rhythm monitoring
WO2016109359A1 (en) *	2014-12-29	2016-07-07	Auspex Pharmaceuticals, Inc.	Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US11013713B2 (en)	2015-12-15	2021-05-25	Vanda Pharmaceuticals Inc.	Method of treatment
WO2017120409A1 (en)	2016-01-06	2017-07-13	Auspex Pharmaceuticals, Inc.	Tetrahydrocarbazole inhibitors of sirt1 receptors
WO2017192843A1 (en)	2016-05-06	2017-11-09	Physician's Seal, LLC	Valerian composition and related methods
US20190216336A1 (en) *	2016-08-18	2019-07-18	Koninklijke Philips N.V.	Blood-pressure management
WO2019028245A1 (en) *	2017-08-02	2019-02-07	Vanda Pharmaceuticals Inc.	USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
CN112074268A (zh) *	2018-03-04	2020-12-11	万达制药公司	用他司美琼治疗疾病
CA3050046C (en)	2018-07-23	2026-04-21	Kobold Corporation	Sleeve valves, shifting tools and methods for wellbore completion operations therewith
CN108828098B (zh) *	2018-07-24	2020-04-21	山东农业大学	一种高效液相色谱-质谱法测定棉花中褪黑素的方法
US20210353586A1 (en) *	2018-09-12	2021-11-18	Vanda Pharmaceuticals Inc.	Improving Sleep or Post-Sleep Performance
KR102260252B1 (ko) *	2018-10-24	2021-06-03	주식회사 인코스팜	피부 세포를 통한 일주기 리듬 분석 방법, 일주기 리듬 장애를 정상화하는 방법 및 일주기 리듬 정보를 이용한 정보제공 시스템
CN109522688B (zh) *	2018-10-27	2023-10-13	平安医疗健康管理股份有限公司	基于数据处理的肾功能衰竭资质认证方法、设备及服务器
EP3671757A1 (en) *	2018-12-18	2020-06-24	Koninklijke Philips N.V.	System and method for determining a level of alertness
CN114641284A (zh) *	2019-06-29	2022-06-17	万带兰制药公司	他司美琼在治疗睡眠异常中的应用
CN114746006B (zh) *	2019-11-25	2025-08-08	株式会社村田制作所	解析系统以及解析方法
EP4072542A1 (en)	2019-12-13	2022-10-19	Vanda Pharmaceuticals Inc.	Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL50699A0 (en)	1975-10-28	1976-12-31	Ici America Inc	Triazole derivatives
DE3466215D1 (en)	1983-05-18	1987-10-22	Univ Monash	The use of melatonin for the manufacture of a medicament
IL79264A0 (en)	1986-06-27	1986-09-30	Univ Ramot	Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en)	1987-02-02	1991-03-05	Eli Lilly And Company	β-alkylmelatonins as ovulation inhibitors
US5093352A (en)	1988-11-14	1992-03-03	Whitby Research, Inc.	Antidepressant agents
US5151446A (en)	1989-09-25	1992-09-29	Northwestern University	Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr)	1990-02-27	1993-12-31	Adir Cie	Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6638963B1 (en) *	1990-12-04	2003-10-28	Oregon Health And Science University	Methods for treating circadian rhythm disorders
US5242941A (en)	1990-12-04	1993-09-07	State Of Oregon	Methods of treating circadian rhythm disorders
IT1251544B (it)	1991-05-13	1995-05-17	Gabriele Biella	Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en)	1993-11-18	2001-01-30	Eli Lilly And Company	Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en)	1994-04-05	1995-04-04	Interneuron Pharmaceuticals, Inc.	Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en)	1994-08-20	1994-10-12	Danbiosyst Uk	Drug delivery compositions
WO1996023496A1 (en)	1995-02-01	1996-08-08	Neurim Pharmaceuticals (1991) Ltd.	Use of melatonin for treating patients suffering from drug addiction
US5932541A (en)	1995-10-24	1999-08-03	Gruenenthal Gmbh	Method of adjusting the circadian rhythm of a mammal
RU2190609C2 (ru)	1996-12-10	2002-10-10	Бристол-Маерс Сквибб Компани	Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции
US5776969A (en)	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
AUPO588297A0 (en) *	1997-03-26	1997-04-24	Luminis Pty Limited	Mediation in melatonin production
JP3055884B2 (ja)	1997-08-07	2000-06-26	花野商事株式会社	引きクランプ装置
DE69910795T2 (de)	1998-06-09	2004-06-17	Takeda Chemical Industries, Ltd.	Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6562858B2 (en)	1999-05-17	2003-05-13	St. Elizabeth's Medical Center Of Boston, Inc.	Method for treating depression
ES2213022T3 (es)	1999-06-30	2004-08-16	Bristol-Myers Squibb Company	Derivados de aminopirrolidina heterociclicos utiles como agentes melatonergicos.
ES2358416T3 (es)	2001-10-30	2011-05-10	Novartis Ag	Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
IL155666A (en)	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment
JP2005080603A (ja) *	2003-09-10	2005-03-31	Kumamoto Technology & Industry Foundation	生体リズム障害の度合の判断方法
US20050137247A1 (en)	2003-12-22	2005-06-23	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of hypertension
EP1696959A2 (en)	2003-12-24	2006-09-06	Sepracor, Inc.	Melatonin combination therapy for improving sleep quality
GB0400031D0 (en) *	2004-01-03	2004-02-04	Univ Sheffield	Depression treatment
AU2006275824B2 (en)	2005-07-29	2010-12-16	Vanda Pharmaceuticals, Inc.	Method of improving wakefulness
US7754902B2 (en)	2006-05-18	2010-07-13	Vanda Pharmaceuticals, Inc.	Ruthenium(II) catalysts for use in stereoselective cyclopropanations
AU2007253704A1 (en)	2006-05-22	2007-11-29	Vanda Pharmaceuticals, Inc.	Treatment for depressive disorders
PT2028937E (pt)	2006-05-22	2015-04-09	Vanda Pharmaceuticals Inc	Tratamento por agonista de melatonina
WO2008011150A1 (en)	2006-07-20	2008-01-24	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
WO2008011120A2 (en)	2006-07-21	2008-01-24	The Regents Of The University Of California	Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008070795A2 (en)	2006-12-06	2008-06-12	Somaxon Pharmaceuticals, Inc.	Combination therapy using low-dose doxepin for the improvement of sleep
SI3461503T1 (sl)	2007-04-11	2022-04-29	Biomarin Pharmaceutical Inc.	Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
EP2195462B1 (en)	2007-09-13	2013-06-12	Vanda Pharmaceuticals Inc.	Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en)	2007-10-19	2009-07-09	Glenmark Generics Limited	Amorphous ramelteon and process for the preparation thereof
EP2215073A4 (en)	2007-10-31	2011-04-06	Merck Sharp & Dohme	SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP5558016B2 (ja)	2009-03-17	2014-07-23	株式会社資生堂	概日リズム調整剤
US20120183610A1 (en) *	2009-04-07	2012-07-19	Lennernaes Hans	glucocorticoid therapy
US20120136050A1 (en)	2009-07-16	2012-05-31	Vanda Pharmaceuticals Inc.	Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en)	2012-01-26	2024-03-05	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
CA3085116C (en) *	2012-01-26	2022-07-19	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
JP5959083B2 (ja)	2012-05-18	2016-08-02	ヴァンダファーマシューティカルズインコーポレイテッド	（１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物
KR102148990B1 (ko)	2012-12-18	2020-08-27	반다 파마슈티칼즈, 인코퍼레이티드.	일주기 리듬 장애의 치료
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
EP3105212A1 (en)	2014-02-12	2016-12-21	Vanda Pharmaceuticals Inc.	Highly purified pharmaceutical grade tasimelteon

2013
- 2013-01-25 CA CA3085116A patent/CA3085116C/en active Active
- 2013-01-25 ES ES13703255T patent/ES2897671T3/es active Active
- 2013-01-25 CN CN201380016258.4A patent/CN104519877A/zh active Pending
- 2013-01-25 US US13/751,011 patent/US8785492B2/en not_active Ceased
- 2013-01-25 EP EP13703255.3A patent/EP2806864B1/en active Active
- 2013-01-25 JP JP2014554894A patent/JP2015508157A/ja active Pending
- 2013-01-25 HU HUE13703254A patent/HUE034876T2/hu unknown
- 2013-01-25 EP EP13703254.6A patent/EP2806863B1/en active Active
- 2013-01-25 KR KR1020197016680A patent/KR102171965B1/ko active Active
- 2013-01-25 KR KR1020197000468A patent/KR20190006598A/ko not_active Ceased
- 2013-01-25 MX MX2014009078A patent/MX374068B/es active IP Right Grant
- 2013-01-25 KR KR1020227020587A patent/KR102593047B1/ko active Active
- 2013-01-25 EP EP17184194.3A patent/EP3300728A3/en not_active Withdrawn
- 2013-01-25 WO PCT/US2013/023315 patent/WO2013112951A2/en not_active Ceased
- 2013-01-25 KR KR1020207005338A patent/KR102307012B1/ko active Active
- 2013-01-25 JP JP2014554893A patent/JP2015509106A/ja active Pending
- 2013-01-25 CN CN202010461784.3A patent/CN111603460A/zh active Pending
- 2013-01-25 CA CA2861111A patent/CA2861111C/en active Active
- 2013-01-25 KR KR1020187024907A patent/KR20180100450A/ko not_active Ceased
- 2013-01-25 ES ES13703254.6T patent/ES2646197T3/es active Active
- 2013-01-25 KR KR1020177013613A patent/KR20170058463A/ko not_active Ceased
- 2013-01-25 DK DK13703254.6T patent/DK2806863T3/en active
- 2013-01-25 RU RU2014134555A patent/RU2631602C2/ru active
- 2013-01-25 BR BR112014018429A patent/BR112014018429A8/pt not_active Application Discontinuation
- 2013-01-25 EP EP19165558.8A patent/EP3620794A1/en active Pending
- 2013-01-25 HR HRP20171600TT patent/HRP20171600T1/hr unknown
- 2013-01-25 MX MX2014009079A patent/MX367184B/es active IP Right Grant
- 2013-01-25 CN CN201910191871.9A patent/CN110215440A/zh active Pending
- 2013-01-25 SI SI201330826T patent/SI2806863T1/sl unknown
- 2013-01-25 KR KR1020217030530A patent/KR102411809B1/ko active Active
- 2013-01-25 IN IN7050DEN2014 patent/IN2014DN07050A/en unknown
- 2013-01-25 AU AU2013211878A patent/AU2013211878A1/en not_active Abandoned
- 2013-01-25 WO PCT/US2013/023312 patent/WO2013112949A2/en not_active Ceased
- 2013-01-25 CN CN201380016945.6A patent/CN104379135B/zh active Active
- 2013-01-25 AU AU2013211880A patent/AU2013211880A1/en not_active Abandoned
- 2013-01-25 EP EP24220196.0A patent/EP4502609A3/en active Pending
- 2013-01-25 BR BR112014018433A patent/BR112014018433A8/pt not_active Application Discontinuation
- 2013-01-25 PT PT137032546T patent/PT2806863T/pt unknown
- 2013-01-25 IN IN7132DEN2014 patent/IN2014DN07132A/en unknown
- 2013-01-25 US US14/374,257 patent/US9549913B2/en active Active
- 2013-01-25 KR KR1020147022612A patent/KR101895653B1/ko active Active
- 2013-01-25 KR KR1020147022609A patent/KR20140117537A/ko not_active Ceased
- 2013-01-25 CA CA3159064A patent/CA3159064A1/en active Pending
- 2013-01-25 RU RU2014134552A patent/RU2650647C2/ru active
- 2013-01-25 CA CA2861108A patent/CA2861108C/en active Active
- 2013-01-25 KR KR1020207030707A patent/KR102317399B1/ko active Active
2014
- 2014-06-11 US US14/301,799 patent/US9060995B2/en active Active
- 2014-06-11 US US14/301,837 patent/US20140296331A1/en not_active Abandoned
- 2014-06-11 US US14/301,918 patent/US20140296332A1/en not_active Abandoned
- 2014-07-17 IL IL233714A patent/IL233714A0/en unknown
- 2014-07-17 IL IL233715A patent/IL233715A0/en unknown
- 2014-07-25 CL CL2014001993A patent/CL2014001993A1/es unknown
- 2014-07-25 MX MX2020007448A patent/MX2020007448A/es unknown
- 2014-07-25 MX MX2019012197A patent/MX2019012197A/es unknown
- 2014-07-25 CL CL2014001992A patent/CL2014001992A1/es unknown
- 2014-08-25 CO CO14186159A patent/CO7131353A2/es unknown
- 2014-08-25 CO CO14186158A patent/CO7131366A2/es unknown
2015
- 2015-04-16 US US14/688,301 patent/US9539234B2/en active Active
2016
- 2016-02-24 US US15/051,978 patent/USRE46604E1/en active Active
- 2016-03-29 JP JP2016066601A patent/JP6267260B2/ja active Active
- 2016-06-20 AU AU2016204178A patent/AU2016204178A1/en not_active Abandoned
- 2016-06-21 AU AU2016204217A patent/AU2016204217A1/en not_active Abandoned
- 2016-09-12 JP JP2016177959A patent/JP2017039731A/ja active Pending
- 2016-12-14 US US15/378,353 patent/US9855241B2/en active Active
- 2016-12-16 US US15/382,526 patent/US10149829B2/en active Active
2017
- 2017-11-26 US US15/822,162 patent/US10449176B2/en active Active
- 2017-12-21 JP JP2017245256A patent/JP2018080181A/ja active Pending
2018
- 2018-02-22 AU AU2018201302A patent/AU2018201302A1/en not_active Abandoned
- 2018-03-16 AU AU2018201909A patent/AU2018201909A1/en not_active Abandoned
- 2018-10-19 JP JP2018197868A patent/JP7119261B2/ja active Active
- 2018-11-05 US US16/180,316 patent/US10610510B2/en active Active
2019
- 2019-06-04 AU AU2019203910A patent/AU2019203910B2/en active Active
- 2019-06-19 AU AU2019204306A patent/AU2019204306A1/en not_active Abandoned
- 2019-09-01 IL IL26905419A patent/IL269054A/en unknown
- 2019-09-01 IL IL26904119A patent/IL269041A/en unknown
- 2019-09-14 US US16/571,106 patent/US10945988B2/en active Active
2020
- 2020-01-31 JP JP2020015452A patent/JP2020097602A/ja active Pending
- 2020-02-16 US US16/792,275 patent/US10980770B2/en active Active
2021
- 2021-01-15 JP JP2021005249A patent/JP2021073222A/ja active Pending
- 2021-02-08 US US17/169,928 patent/US11633377B2/en active Active
- 2021-03-19 US US17/206,811 patent/US11833130B2/en active Active
- 2021-07-06 US US17/368,160 patent/US11285129B2/en active Active
- 2021-07-08 AU AU2021204784A patent/AU2021204784B2/en active Active
2022
- 2022-02-15 US US17/651,233 patent/US11826339B2/en active Active
- 2022-02-15 US US17/651,231 patent/US11850229B2/en active Active
- 2022-02-15 US US17/651,232 patent/US11918556B2/en active Active
- 2022-03-16 JP JP2022041570A patent/JP2022095662A/ja active Pending
2023
- 2023-02-13 JP JP2023020257A patent/JP2023071727A/ja active Pending
2024
- 2024-01-18 US US18/416,734 patent/US20240197671A1/en not_active Abandoned
- 2024-01-18 US US18/416,748 patent/US12201604B2/en active Active
2025
- 2025-01-17 US US19/027,122 patent/US20250161259A1/en active Pending

Also Published As

Publication number	Publication date
HUE034876T2 (hu)	2018-03-28
AU2019204306A1 (en)	2019-07-04
KR20220087582A (ko)	2022-06-24
PT2806863T (pt)	2017-11-09
KR20170058463A (ko)	2017-05-26
AU2016204217A1 (en)	2016-07-14
CN104379135B (zh)	2020-07-14
KR102317399B1 (ko)	2021-10-26
CA2861111A1 (en)	2013-08-01
CO7131366A2 (es)	2014-12-01
US11850229B2 (en)	2023-12-26
JP2018080181A (ja)	2018-05-24
EP3300728A2 (en)	2018-04-04
US20150216837A1 (en)	2015-08-06
RU2014134555A (ru)	2016-03-20
CN110215440A (zh)	2019-09-10
KR20200022543A (ko)	2020-03-03
US20240197671A1 (en)	2024-06-20
MX2014009079A (es)	2016-01-25
JP2023071727A (ja)	2023-05-23
EP3620794A1 (en)	2020-03-11
AU2019203910B2 (en)	2021-09-23
BR112014018429A2 (es)	2017-06-20
JP2021073222A (ja)	2021-05-13
KR101895653B1 (ko)	2018-09-05
US9060995B2 (en)	2015-06-23
WO2013112951A2 (en)	2013-08-01
KR20210118983A (ko)	2021-10-01
CL2014001992A1 (es)	2015-03-13
JP2019038822A (ja)	2019-03-14
US9855241B2 (en)	2018-01-02
ES2897671T3 (es)	2022-03-02
JP7119261B2 (ja)	2022-08-17
US8785492B2 (en)	2014-07-22
KR20200123873A (ko)	2020-10-30
US10149829B2 (en)	2018-12-11
US20220168264A1 (en)	2022-06-02
US10610510B2 (en)	2020-04-07
MX2019012197A (es)	2020-08-31
US20140357710A1 (en)	2014-12-04
ES2646197T3 (es)	2017-12-12
MX2014009078A (es)	2016-01-25
JP2015508157A (ja)	2015-03-16
WO2013112949A2 (en)	2013-08-01
US10945988B2 (en)	2021-03-16
JP2020097602A (ja)	2020-06-25
WO2013112949A3 (en)	2013-09-19
IL269054A (en)	2019-10-31
CO7131353A2 (es)	2014-12-01
IN2014DN07050A (es)	2015-04-10
MX2020007448A (es)	2020-09-14
BR112014018429A8 (pt)	2017-07-11
EP2806864A2 (en)	2014-12-03
AU2018201302A1 (en)	2018-03-15
MX374068B (es)	2020-07-30
US20140296332A1 (en)	2014-10-02
US12201604B2 (en)	2025-01-21
RU2650647C2 (ru)	2018-04-16
US20210161854A1 (en)	2021-06-03
US9539234B2 (en)	2017-01-10
US20140296330A1 (en)	2014-10-02
KR102593047B1 (ko)	2023-10-24
CL2014001993A1 (es)	2015-03-13
AU2021204784A1 (en)	2021-08-05
MX367184B (es)	2019-08-08
KR20140116927A (ko)	2014-10-06
US20130197076A1 (en)	2013-08-01
US11826339B2 (en)	2023-11-28
CA3159064A1 (en)	2013-08-01
US20220168263A1 (en)	2022-06-02
USRE46604E1 (en)	2017-11-14
CA2861108A1 (en)	2013-08-01
EP4502609A3 (en)	2025-04-09
US20190070144A1 (en)	2019-03-07
CN104519877A (zh)	2015-04-15
KR102171965B1 (ko)	2020-10-30
US9549913B2 (en)	2017-01-24
AU2018201909A1 (en)	2018-04-12
KR20140117537A (ko)	2014-10-07
KR102411809B1 (ko)	2022-06-22
HRP20171600T1 (hr)	2017-12-15
US10980770B2 (en)	2021-04-20
US11918556B2 (en)	2024-03-05
AU2016204178A1 (en)	2016-07-14
CA3085116A1 (en)	2013-08-01
KR102307012B1 (ko)	2021-09-30
EP2806864B1 (en)	2021-08-25
EP2806863A2 (en)	2014-12-03
US11633377B2 (en)	2023-04-25
DK2806863T3 (en)	2017-10-30
JP2022095662A (ja)	2022-06-28
KR20190006598A (ko)	2019-01-18
IL269041A (en)	2019-10-31
EP3300728A3 (en)	2018-05-02
SI2806863T1 (sl)	2017-12-29
US20180071245A1 (en)	2018-03-15
US20210205261A1 (en)	2021-07-08
US20200179326A1 (en)	2020-06-11
CN111603460A (zh)	2020-09-01
JP2015509106A (ja)	2015-03-26
US20140296331A1 (en)	2014-10-02
AU2021204784B2 (en)	2024-11-14
CA2861111C (en)	2021-11-23
US20210330634A1 (en)	2021-10-28
AU2013211878A1 (en)	2014-08-21
JP2016172737A (ja)	2016-09-29
US10449176B2 (en)	2019-10-22
RU2014134552A (ru)	2016-03-20
CN104379135A (zh)	2015-02-25
CA3085116C (en)	2022-07-19
US20220175716A1 (en)	2022-06-09
IL233715A0 (en)	2014-09-30
JP2017039731A (ja)	2017-02-23
US20170100366A1 (en)	2017-04-13
US11285129B2 (en)	2022-03-29
BR112014018433A2 (es)	2017-06-20
JP6267260B2 (ja)	2018-01-24
WO2013112951A3 (en)	2014-12-31
AU2019203910A1 (en)	2019-06-20
EP4502609A2 (en)	2025-02-05
US20240156775A1 (en)	2024-05-16
BR112014018433A8 (pt)	2017-07-11
KR20180100450A (ko)	2018-09-10
US11833130B2 (en)	2023-12-05
KR20190069617A (ko)	2019-06-19
US20250161259A1 (en)	2025-05-22
US20200009106A1 (en)	2020-01-09
EP2806863B1 (en)	2017-08-09
CA2861108C (en)	2020-09-08
IL233714A0 (en)	2014-09-30
RU2631602C2 (ru)	2017-09-25
AU2013211880A1 (en)	2014-08-21
US20170087123A1 (en)	2017-03-30

Publication	Publication Date	Title
IN2014DN07050A (es)	2015-04-10
MX2020012689A (es)	2021-02-15	Tratamiento de trastornos del ritmo circadiano.
PH12014501997A1 (en)	2014-11-24	Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2015011296A (es)	2016-04-04	Dispositivo foto-terapeutico, metodo y uso.
CL2016000354A1 (es)	2016-08-19	Modulación de la inmunidad tumoral
PL2780073T3 (pl)	2018-05-30	Aparat do łagodzenia bólu z zastosowaniem przezskórnej elektrostymulacji nerwów
EA201500314A1 (ru)	2015-12-30	Лекарственные формы энзалутамида
AU347019S (en)	2013-02-18	Sexual stimulation device
NZ701607A (en)	2017-04-28	Therapeutic use of chardonnay seed products
PH12015502302A1 (en)	2016-02-15	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015008454A (es)	2016-05-16	Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
EA201591185A1 (ru)	2016-02-29	Применение пидотимода для лечения псориаза
IN2014KN01772A (es)	2015-10-23
NZ631749A (en)	2015-06-26	Methods of treating cancer using angiogenin or an angiogenin agonist
EA201591184A1 (ru)	2015-10-30	Применение пидотимода для лечения атопического дерматита
UA87193U (ru)	2014-01-27	Способ лечения наркотической зависимости
AU351421S (en)	2013-10-21	Frame profile